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ABSTRACT 
 
The main objective of this work was to study the effects of monosodium 
glutamate (MSG), which is the main constituent of many processed food such as andomie 
noodles, on plasma insulin, glucose levels and its toxicity in Wistar albino rats. Thirty- 
two Wistar albino rats, from either sex, were weighed and randomly divided into four 
even groups. One group was left as control and the other three groups were orally treated 
daily for four weeks using gastric tube with three different doses of MSG (120, 240 and 
480 mg/kg body weight. Clinical symptoms were observed. The plasma glucose and 
insulin levels were measured after four weeks of treating by MSG. Two milligrams per 
kilogram of glucose solution (500/0) was intraperitonially injected to all rats. After two 
hours from glucose load, the plasma glucose and insulin levels were measured. All the 
rats in the groups were weighed after four weeks. The rats from all groups were -then- 
sacrificed and slices from the brain, liver, kidney and pancreas were fixed in 10% neutral 
formalin for histopathological examination. The result revealed that there were no clinical 
signs in the control or treated groups as well as no significant differences in body weights 
of the rats at the beginning and the end of the experiment. In the groups treated with 120 
and 480 mg/kg Bwt of MSG, there were slight changes in insulin and glucose levels but 
were not significant. Only the group that was treated with 240 mg/kg Bwt showed 
significant increase in plasma glucose and insulin levels (hyperinsulinemia/ 
hyperglycemia). Hence in this study glutamate causes insulin resistant but in certain dose. 
However, it was reported that insulin resistant in glutamate treated animal could be due to 
changes in insulin binding or postreceptor insulin effects in target tissues. Further study 
can be done in this area. Histopathological changes were similar in all three groups that 
were treated with MSG and more severe as the dose is increased. In the liver there were 
vacuolization, congestion, dilatation of sinusoid and disorganization. In the brain, there 
were congestion, oedema around neurons, and demyelination. Congestion, haemorrhage, 
tubular dilatation and proteinous material in tubules were observed in the kidney. The 
pancreas showed hyperplasia of langerhans cells and extensive haemorrhages. It is 
concluded that MSG caused hyperinsulinemia and hyperglycemia i.e. insulin resistance at 
240 mg/kg Bwt beside hepatotoxicity and nephrotoxicity as well as toxicity in the brain 
and pancreas. It is recommended that further investigations to be conducted to confirm 
the insulin resistance.  
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INTRODUCTION 
Monosodium glutamate is the sodium salt of non-essential amino acid, glutamate, 
one of the most abundant amino acids found in nature. Glutamate is thus found in a wide 
variety of foods, in a free form. Because of its flavour enhancing effects it is widely used 
in much food stuffs, particularly processed foods either as purified monosodium salt or as 
a component of a mixture of amino acids and small peptides resulting from acidic or 
enzymatic hydrolysis of protein. MSG is now used by most fast food chains and in many 
foodstuffs. It has been implicated as a causative agent in the symptoms complex known 
as Chinese restaurant syndrome (Kwok, 1968).  In some studies, MSG was found to 
induce hypothalamic lesions and leptin resistance, possibly influencing energy balance, 
leading to overweight. Over dose of MSG can increase both insulin secretion and blood 
glucose level suggesting presence of insulin resistance (Nonaka and Oki 1987;  Ka He1 et 
al., 2008). The purpose of this study was to confirm the effect of MSG on plasma glucose 
and insulin levels and any possible potential cause of insulin resistance and to determine 
MSG toxic effects in Wister albino rats.  
MATERIALS AND METHODS 
Monosodium glutamate (MSG), white granular crystalline form, was brought 
from Bahary Central Market, Sudan. Thirty two healthy Wister albino rats of both sexes 
were used. They were housed under standard conditions and had free access to water and 
standard diet. They were left for two weeks as adaptation period.  At the end of the 
adaption period the rats were weighed and randomly divided into 4 groups, of 8 rats each. 
Group A was left as a control group, while groups B, C and D were orally given MSG, 
using gastric tubes at concentrations of 120, 240 and 480 mg/Kg body weight, 
respectively daily for 4 weeks.  Plasma glucose and insulin levels were determined at 
zero hours. 50% glucose solution was intraperitonilly injected at dose of 2 mg/Kg to all 
rats. The plasma glucose and insulin levels were measured at 1 and 2 hours after glucose 
load.   Slices from pancreas, livers, kidneys and brains were collected and fixed in 10% 
neutral buffered formalin for histopathological investigation. One to two ml blood were 
drawn out with the capillary tubes from the orbital plexus of the rats into heparinized 
tubes. The blood was centrifuged at 3000 rpm for 5 min to separate the plasma which was 
stored and used for determination of glucose and insulin concentrations.  All animals 
were weighed at the beginning and the end of the experiment. Plasma glucose level was 
measured by Glucose Oxidation Method, GOD/PAP. The glucose concentration in 
plasma was measured by an enzymatic method, according to Siest and schielf (1981). 
Glucose was determined after enzymatic oxidation in presence of glucose 
oxidase. The hydrogen peroxidase formed reacted, under catalysis of peroxidase, with 
phenol and 4-aminophenazone to form a red violet quinoneimine dye as indicator. 
Glucose + 𝑂2+𝐻2𝑂
𝐺𝑙𝑢𝑐𝑜𝑠𝑒  𝑜𝑥𝑖𝑑𝑎𝑠𝑒     
              gluconic acid + 𝐻2𝑂2 
2𝐻2𝑂2 + 4- aminophenazone
𝑝ℎ𝑒𝑛𝑜𝑙  𝑝𝑒𝑟𝑜𝑥𝑖𝑑𝑎𝑠𝑒    
                quinonneimine +4𝐻2𝑂 
Twenty microlitres of the standard or the sample were pipetted into test tubes and 
2000 µl of the reagent were added to each tube and mixed. The mixture was incubated for 
5 minutes at 37ºC.  The absorbance of the standard (𝐴𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑  ) and of the 
sample(𝐴𝑠𝑎𝑚𝑝𝑙𝑒 ) was read against the reagent blank at wavelength 490 nm. Glucose 
concentration (mg /dl) =
𝐴(𝑠𝑎𝑚𝑝𝑙𝑒 )
𝐴 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑  
× 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛.  Insulin concentration 
in plasma was measured by Ultra-Sensitive Rat Insulin ELISA Kit. 
Rat insulin in the sample was bound to a guinea pig anti-insulin antibody coated on 
the microplate well and the unbound material was removed by washing. Horse radish 
peroxidase (POD) –conjugated anti-insulin antibody was added to the guinea pig anti-
insulin antibody/rat insulin complex in the microplate wells. The excess POD-conjugate 
was removed by washing. The bound POD conjugated in the micro plate wells is detected 
by the addition of the tetramethylbenizidine (TMB) substrate solution. 
Ninety five microlitres of sample diluents were dispensed in each well (Fig. 9). 
Then, 5 µl samples were pipetted into the wells. The plates were incubated for 2 hours at 
4ºC before the wells were washed 5 times using 300 µl wash buffer (Wash Buffer Stock 
Solution mixed with 1L distilled water). One hundred microlitres of anti–insulin enzyme 
conjugate were dispensed per well, then, the wells were incubated for 30 min at room 
temperature. The wells were washed again 7 times using the wash buffer. One hundred 
microlitres of the enzyme substrate solution were immediately dispensed and incubated 
for 40 min at room temperature in a dark place. The absorbance was determined via 
interpolation using the standard curve generated by plotting absorbance. Slices from 
livers, kidneys, pancreas and brains were collected and fixed in 10% neutral buffered 
formalin (Sodium hydrogen 605 g/l and Sodium dihydrogen 4.0 g/l), then, embedded in 
paraffin wax, sectioned at 5 µm and stained with Hematoxyline and Eosin (H&E) 
according to Culling (1974).  Data were analyzed statistically with Completely 
Randomized AOVA by Statistix 8 program, v.8.0 (2003). 
RESULTS 
There were no clinical signs observed in the control or treated groups and there 
were no significant differences in body weights between control and treated ones (Table 
1. and Fig 10). However, the rate of weight gain in the control rats was 13.6% compared 
to groups C  and D treated with 240 mg/kg Bwt of MSG and 480 mg/kg Bwt of MSG  
which were 15.5% and 15.7%, respectively. There was a slight increase of 27.4% in the 
rate of weight gain in group B which was not significant.  The mean changes in plasma 
glucose level in various groups are illustrated in Table (2) and Fig. (11). After four weeks 
of treatment with MSG, no significant changes were determined in plasma glucose level 
in group B (treated with 120 mg/kg of MSG) and group D (treated with 480 mg/kg of 
MSG); however, group C (treated with 240 mg/kg of MSG) showed a significant 
difference (P < 0.05).  The rate of increase of plasma glucose level in the control group 
one hour after glucose loading was 19% compared to groups that treated with 120mg/kg 
of MSG, 240mg/kg  and 480mg/kg of  which were 39% ,32.9% and 20% respectably.    
Two hours after glucose loading, plasma glucose level decreased by 8% in the 
control group and in the group that had received 120 mg/Kg of MSG it decreased by 
4.8%. However, in groups C and D, the plasma glucose level increased after 2 hours of 
glucose loading in group C by 55.7% which was highly significant (P< 0.05).  In group 
D, the plasma glucose level was increased by 5%. 
 
Plasma insulin level 
The changes in plasma insulin levels were illustrated in (Table3 and Fig12). 
Plasma insulin levels increased insignificantly in all groups, except the group that was 
treated with 240mg/kg of MSG. The basal insulin concentration did not differ in the 
control group and MSG treated groups. After one hour from glucose loading, there was 
insignificant increase in the treated groups compared to the control. Two hours from 
glucose loading, insulin was significantly different (P < 0.05) in the group that was 
treated with 240mg/Kg of MSG compared with the control group, but insignificant in the 
groups that had been treated with 120mg/Kg and 480mg/Kg. 
 
Histopathological Findings 
There were histopathological changes in all groups that had received MSG but the 
intensity increased as the doses increased. Livers showed congestion disorganization and 
dilatation of sinusoid (Figs. 14, 16 and 19). The kidneys showed hemorrhage, tubular 
dilatation and presence of proteinous material in the tubules (Fig 17). There were 
vacuolation, demylization in the brains and odema around the neurons (Figs. 13 and 18).  
In pancreas there was a hyperplasia of langerhans cells and hemorrhages (Figs. 15 and 
20). 
 
DISCUSSION 
The groups that had been treated with MSG didn’t show any clinical symptoms. 
These results were similar to those reported by Morselli and Garattini (1970) who 
concluded that there was no evidence that MSG could cause any clinical symptoms. In 
contrast, Kenney (1986) and Tarasoff and Kelly (1993) noted that a reaction might occur 
to an extremely large dose of MSG but usually transit and benign. Selma (2009) reported 
clinical symptoms of shiver, dizziness, disorientation and paralysis) in rats treated with 
MSG. There was no significant effect on body weight in rats treated by MSG in this 
study. Similar to the results noted by Hara et al. (1962), after administration of different 
doses of MSG orally to rats once a day for 80 days. Selma (2009) concluded that MSG 
had no effect on body weight. Group of rats that had received 240 mg/kg BW of MSG 
showed the highest plasma insulin level and the highest plasma glucose level. The 
elevation in blood insulin level which was detected in the group that had received 240 
mg/kg BW of MSG, was similar to the results reported by Hirata et al. (1997) who 
observed that after the glucose load, plasma insulin concentration reached the highest 
values in MSG-treated rats. The increases in insulin level could be attributed to the 
presence of glutamate receptors in β pancreatic cell (Brice et al., 2002). Those authors 
found that Endogenous activation of mGlu5 receptors (glutamate receptor) was 
permissive to glucose-stimulated intracellular Ca release and insulin secretion.  Mice 
lacking mGlu5 receptors or treated with a selective mGlu5 receptor antagonist showed a 
blunted insulin response to glucose. 
Another theory was suggested by Yukio et al. (2002), that glutamate alone does 
not stimulate insulin secretion. The activation of glutamate dehydrogenase enzyme 
(GDH), stimulates the conversion of glutamate to α- ketoglutarate and play more 
important role in insulin secretion. GDH enhances glutamate oxidation and increases 
ATP production by providing the TCA cycle with substrate (α-ketoglutarate) and 
therefore stimulates insulin secretion. Yukio et al. (2002) reported that any mutation in 
the gene that coded for GDH could cause hyperinsulinism/hyperammonemia (HI/HA) 
syndrome. HI/HA syndrome is characterized by hyperinsulinemic hypoglycemia 
accompanied by mild, asymptomatic hyperammonemia. In this study the MSG- treated 
rats exhibited hyperglycemia instead of hypoglycemia.  
The presence of hyperinsulinemia/ hyperglycemia in MSG-treated rats was 
detected also by Hirata et al. (1997) and Hugues et al. (2002). They found that glutamate 
did not lower blood glucose level despite the rise in insulin secretion to a very higher 
value. They suggested that glutamate caused insulin resistance. In an insulin-resistant 
person, normal levels of insulin do not have the same effect in controlling blood glucose 
levels. During the compensated phase on insulin resistance insulin levels are higher, and 
blood glucose levels are still maintained. If compensatory insulin secretion fails, then 
either fasting (impaired fasting glucose) or postprandial (impaired glucose tolerance) 
glucose concentrations increase. Insulin itself leads to a kind of insulin resistance, a 
higher level of insulin than usual, that can lead to a kind of positive feedback, increases 
the need for insulin and causes down regulation of Glut4 receptor (www.Wikipedia.com).  
Insulin resistance in glutamate treated group could also be due to changes in 
insulin binding or postreceptor insulin effects in target tissues (Macho et al. 2000). There 
was also an impairment in glucose adipose tissue uptake in MSG- treated rats due to 
decrease in GLUT4 in fat cell (Macho et. al. 2000) and there was also a significant 
reduction in GLUT4 in skeletal muscle, cardiac muscle and brown adipose tissue in mice 
(Machado et al. 1993). Macho et al. (2000) reported that there was a decrease in the 
number of insulin receptors in target tissues in MSG- treated rats. They found lower 
values of binding capacity of insulin receptor in adipocytes, skeletal muscle and liver 
tissues. This lowering could be due to down regulation of insulin receptor by 
hyperinsulinemia.  
A pancreatic cell hyperplasia was observed in MSG treated rats. This is to  
Mitsunbo et al. (2006) who observed a pancreatic islet hypertrophy in MSG- treated rats. 
This may explain the elevation in insulin secretion in MSG treated rats. The lesions found 
in the brains are signs of brain toxicity. These findings are similar to those of Olney 
(1969) who reported that MSG treatment caused brain lesions, particularly acute neuronal 
necrosis in several regions of the developing brain of neonatal mice. van Marani and 
Rietveld (1986) also confirmed that MSG induces neurotoxicity. 
In this study, MSG induced liver and kidney lesions. Inuwa et al. (2011) reported 
that MSG caused hepatotoxicity and nephrotoxicity. They found increases in some 
biochemical parameters like plasma enzymes (Glutamate Oxaloacetate Transaminase 
SGOT, Glutamate Pyruvate Transaminase (GPT), Alkaline Phosphatase (ALP) and 
Lactose Dehydrogenase (LDH)) due to administration of MSG to adult Wister albino 
rats. These elevations in plasma enzymes indicate that there was a hepato-cell damage. 
They also reported a remarkable elevated level of urea and creatinine within the MSG 
treated rats when compared with the control. Serum urea and creatinine increase as the 
ability of the kidney to filter fluid within the body declines and they concluded that there 
was a possible link between MSG and Renal impairment. 
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Table 1. Mean body weights of rats treated with various levels of Monosodium 
Glutamate  
 
Means ± SD. Means within the same column having the similar superscript are not 
significantly variable at (P> 0.05 ).  
 
 
 
Fig 1.  Microplate for insulin detection by ELISA kits 
 
       MSG Doses  
     (mg/kg Bwt)   
Before dosing After dosing Weight gain (%) 
( 0 ) 73.750±11.877a 83.750±15.979a 13.6 
(120 ) 75.714±19.457a 96.429±20.759a 27.4 
(240) 78.571±15.468a 90.714±15.391a 15.5 
(480) 80.286±14.044a 92.857±16.941a 15.7 
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Fig 2. The Mean body weights of rats treated with various levels of Monosodium 
glutamate. 
 
 
 
 
 
Means ± SD. Means within the same column having the similar superscript are not 
significantly variable at (P> 0.05 ).  
 
 
 
 
 
Fig 3. The Mean plasma glucose level in rats treated with various doses of MSG 
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 (120)  88.014 ± 1.240a 122.612 ± 2.153a 116.557 ± 2.719b  
 (240) 95.511 ± 1.252a  126.981 ± 4.382a 179.721 ± 7.296a 
(480) 95.741± 1.175a 114.922 ± 1.490a 120.663 ± 2.899b 
  
 
 
 
Means ± SD. Means within the same column having the similar superscript are not 
significantly variable at (P> 0.05 ).  
 
 
 
Fig 4. The mean plasma insulin level in rats treated with various doses of MSG 
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Fig 5. Brain from rat received 120 mg/kg BW of MSG note, presence of vacuolation. 
 
 
 
 
 
Fig 6. Liver from rat received 120 mg/kg BW of MSG note, presence of 
vacuolation and disorganization  
 
  
Fig 7. Pancreas from rat received 120 mg/kg BW of MSG note langerhans cells 
hyperplesia. 
 
 
 
Fig 8. Liver from rat received 240mg/kg BW of MSG note, presence of vacuolation, 
congestion and disorganization.  
  
 
Fig 9. Kidney from rat received 240mg/kg BW of MSG note, congestion, porteination 
material in tubules and glumerular less cellular. 
 
 
Fig 10. Brain from rat received 480mg/kg BW of MSG note, congestion, vaculation, 
demyelination and odema around the neruron 
  
 
 
Fig 11. Liver from rat received 480mg/kg BW of MSG note, congestion, disorganization 
and sinusoidal dilatation.  
 
 
Fig 12. Pancreas from rat received 480mg/kg BW of MSG note, hemorrhage and 
langerhans cells hyperplasia. 
